Search research articles
Contact Us
Filters
Showing results (71-80 of 124) with videos related to
Page
of 13
Sort By:
Annals of Neurology
|
April 13, 2000
Pathophysiology of levodopa-induced dyskinesias in Parkinson's disease: problems with the current model
J A Obeso, M C Rodriguez-Oroz, M Rodriguez, et al.
Annals of Neurology
|
September 28, 1998
A fluorescent double-labeling method to detect and confirm apoptotic nuclei in Parkinson's disease
N A Tatton, A Maclean-Fraser, W G Tatton, et al.
Biological Trace Element Research
|
December 24, 1997
Intranigral iron infusion in the rat. Acute elevations in nigral lipid peroxidation and striatal dopaminergic markers with ensuing nigral degeneration
G J Sengstock, N H Zawia, C W Olanow, et al.
Journal of Neural Transmission (Vienna, Austria : 1996)
|
October 14, 2004
Effects of levodopa on cognitive functioning in moderate-to-severe Parkinson's disease (MSPD)
C E Morrison, J C Borod, M F Brin, et al.
Journal of Neuroscience Research
|
May 1, 1993
Infusion of iron into the rat substantia nigra: nigral pathology and dose-dependent loss of striatal dopaminergic markers
G J Sengstock, C W Olanow, R A Menzies, et al.
The American Journal of Psychiatry
|
December 1, 1981
"On-off" syndrome treated with lithium carbonate: a case report
D R Ross, C E Coffey, E L Ferren, et al.
Annals of Neurology
|
October 1, 1982
Treatment of the "on-off" phenomenon in Parkinsonism with lithium carbonate
C E Coffey, D R Ross, E L Ferren, et al.
Neurology
|
January 9, 2001
The evolution and origin of motor complications in Parkinson's disease
J A Obeso, M C Rodriguez-Oroz, P Chana, et al.
Movement Disorders : Official Journal of the Movement Disorder Society
|
June 1, 2000
Time course of loss of clinical benefit following withdrawal of levodopa/carbidopa and bromocriptine in early Parkinson' s disease
R A Hauser, W C Koller, J P Hubble, et al.
Archives of Neurology
|
October 13, 2004
Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease
C W Olanow, K Kieburtz, M Stern, et al.
Page
of 13
Search research articles
Search
Showing results (71-80 of 124) with videos related to
Sort By:
Page
of 13
Annals of Neurology
|
April 13, 2000
Pathophysiology of levodopa-induced dyskinesias in Parkinson's disease: problems with the current model
J A Obeso, M C Rodriguez-Oroz, M Rodriguez, et al.
Annals of Neurology
|
September 28, 1998
A fluorescent double-labeling method to detect and confirm apoptotic nuclei in Parkinson's disease
N A Tatton, A Maclean-Fraser, W G Tatton, et al.
Biological Trace Element Research
|
December 24, 1997
Intranigral iron infusion in the rat. Acute elevations in nigral lipid peroxidation and striatal dopaminergic markers with ensuing nigral degeneration
G J Sengstock, N H Zawia, C W Olanow, et al.
Journal of Neural Transmission (Vienna, Austria : 1996)
|
October 14, 2004
Effects of levodopa on cognitive functioning in moderate-to-severe Parkinson's disease (MSPD)
C E Morrison, J C Borod, M F Brin, et al.
Journal of Neuroscience Research
|
May 1, 1993
Infusion of iron into the rat substantia nigra: nigral pathology and dose-dependent loss of striatal dopaminergic markers
G J Sengstock, C W Olanow, R A Menzies, et al.
The American Journal of Psychiatry
|
December 1, 1981
"On-off" syndrome treated with lithium carbonate: a case report
D R Ross, C E Coffey, E L Ferren, et al.
Annals of Neurology
|
October 1, 1982
Treatment of the "on-off" phenomenon in Parkinsonism with lithium carbonate
C E Coffey, D R Ross, E L Ferren, et al.
Neurology
|
January 9, 2001
The evolution and origin of motor complications in Parkinson's disease
J A Obeso, M C Rodriguez-Oroz, P Chana, et al.
Movement Disorders : Official Journal of the Movement Disorder Society
|
June 1, 2000
Time course of loss of clinical benefit following withdrawal of levodopa/carbidopa and bromocriptine in early Parkinson' s disease
R A Hauser, W C Koller, J P Hubble, et al.
Archives of Neurology
|
October 13, 2004
Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease
C W Olanow, K Kieburtz, M Stern, et al.
Page
of 13